1. Home
  2. BETR vs MYGN Comparison

BETR vs MYGN Comparison

Compare BETR & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Better Home & Finance Holding Company

BETR

Better Home & Finance Holding Company

HOLD

Current Price

$25.47

Market Cap

538.7M

Sector

Finance

ML Signal

HOLD

Logo Myriad Genetics Inc.

MYGN

Myriad Genetics Inc.

HOLD

Current Price

$3.57

Market Cap

444.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BETR
MYGN
Founded
2014
1991
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
538.7M
444.2M
IPO Year
N/A
1996

Fundamental Metrics

Financial Performance
Metric
BETR
MYGN
Price
$25.47
$3.57
Analyst Decision
Buy
Buy
Analyst Count
1
7
Target Price
$40.00
$7.64
AVG Volume (30 Days)
549.9K
1.5M
Earning Date
05-07-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$771,400,000.00
Revenue This Year
$55.02
$6.86
Revenue Next Year
$65.66
$5.45
P/E Ratio
N/A
N/A
Revenue Growth
N/A
2.33
52 Week Low
$10.81
$3.53
52 Week High
$94.06
$8.59

Technical Indicators

Market Signals
Indicator
BETR
MYGN
Relative Strength Index (RSI) 33.42 30.43
Support Level N/A N/A
Resistance Level $35.07 $5.30
Average True Range (ATR) 2.88 0.27
MACD -1.65 -0.11
Stochastic Oscillator 4.01 0.00

Price Performance

Historical Comparison
BETR
MYGN

About BETR Better Home & Finance Holding Company

Better Home & Finance Holding Co is a technology-enabled homeownership company that provides mortgage, home equity, and related services through a digital platform. The company operates through two reportable segments: Home Finance, which focuses on residential mortgage origination, including purchase, refinance, and home equity products, generating revenue mainly from loan sales; and Banking, which, through its U.K. subsidiary Birmingham Bank, offers a range of financial products and services to consumers and small businesses. It generates the majority of its revenue from the Home Finance segment.

About MYGN Myriad Genetics Inc.

Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.

Share on Social Networks: